Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The routine administration of 75 mg of intravenous aminophylline in patients with severe chronic kidney disease undergoing a nuclear stress test with regadenoson (Lexiscan®) can reduce or eliminate the incidence of diarrhea and other side effects related to regadenoson.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rush University Medical Center
• Collaborator: John H. Stroger Hospital
• Treatments: Aminophylline; Regadenoson

Criteria

Inclusion Criteria:

• Adult patients referred to undergo a clinically-indicated regadenoson-stress myocardial perfusion imaging at Rush University Medical Center

• Stage IV or V chronic kidney disease (GFR < 30, hemodialysis, and/or peritoneal dialysis).

Exclusion Criteria:

• Patient refusal to participate

• Known allergic reaction to aminophylline.

• Pre-existing headache or acute/subacute GI illness with symptoms of diarrhea, abdominal discomfort, nausea or vomiting.

• Any contraindication to aminophylline: hypotension, unstable cardiac arrhythmias and acute coronary symptoms.

• Uncontrolled seizure disorder defined as more than 2 seizure episodes in the past 12 months or any seizure in the past week.

• Pregnant or breast-feeding women.

• Patients receiving anti-platelet agent dipyridamole (Persantine® or Aggrenox®).